Literature DB >> 16097045

Effect of IL-10 on the expression of HSC growth factors in hepatic fibrosis rat.

Mei-Na Shi1, Wei-Da Zheng, Li-Juan Zhang, Zhi-Xin Chen, Xiao-Zhong Wang.   

Abstract

AIM: To study the effect of IL-10 on the expression of growth factors--transforming growth factor-beta1 (TGF-beta1), epidermal growth factor (EGF), hepatocyte growth factor (HGF) and platelet-derived growth factor (PDGF) of hepatic stellate cells (HSCs) of hepatic fibrosis rat and the anti-fibrogenic role of exogenous IL-10.
METHODS: Hepatic fibrosis was induced by CCl(4) administration intra-peritoneally. Sixty clean male Sprague-Dawley (SD) rats were randomly divided into three groups: normal control group (GN, 8 rats), hepatic fibrosis model group (GC, 28 rats) and IL-10 treated group (GI, 24 rats). At the beginning of the 7th and 11th wk, rats in each group were routinely perfused with pronase E and type IV collagenase through a portal vein catheter and the suspension obtained from the liver was spun by centrifugation with 11% Nycodenz density gradient to isolate HSCs. Histological examination was used to determine the degree of hepatic fibrosis. RT-PCR was employed to analyze mRNA expression from freshly isolated cells. Immunocytochemistry was performed to detect protein expression in primary cultured HSCs.
RESULTS: Rat hepatic fibrosis was developed with the increase of injection frequency of CCl(4), and HSCs were successfully isolated. At the 7th and 11th wk, TGF-beta1, EGF, and HGF mRNA in GC increased obviously compared with GN (P = 0.001/0.042, 0.001/0.001, 0.001/0.001) and GI (P = 0.001/0.007, 0.002/0.001, 0.001/0.001). For TGF-beta1, no difference was observed between GI and GN. For EGF, mRNA level in GI increased compared with GN during the 7th wk (P = 0.005) and 11th wk (P = 0.049). For HGF, mRNA level in GI decreased compared with GN at the 7th wk (P = 0.001) and 11th wk (P = 0.021). Between these two time points, TGF-beta1 expression at the 7th wk was higher than that of the 11th wk (P = 0.049), but for EGF, the former was lower than the latter (P = 0.022). As for PDGF mRNA, there was no significant difference between these groups, but difference seemed to exist in protein levels. Results by immunocytochemistry of TGF-beta1 and EGF were paralleled with the above findings.
CONCLUSION: The expression of TGF-beta1, EGF and HGF increased in HSC of hepatic fibrosis rat and decreased after treatment with IL-10. IL-10 plays an anti-fibrogenic role by suppressing growth factors expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097045      PMCID: PMC4398723          DOI: 10.3748/wjg.v11.i31.4788

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Hepatic fibrosis - therapeutic strategies.

Authors:  D Schuppan; D Strobel; E G Hahn
Journal:  Digestion       Date:  1998 Jul-Aug       Impact factor: 3.216

Review 2.  Signal transduction in hepatic stellate cells.

Authors:  M Pinzani; F Marra; V Carloni
Journal:  Liver       Date:  1998-02

3.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats.

Authors:  T Ueki; Y Kaneda; H Tsutsui; K Nakanishi; Y Sawa; R Morishita; K Matsumoto; T Nakamura; H Takahashi; E Okamoto; J Fujimoto
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells.

Authors:  A Ledeboer; J J Brevé; S Poole; F J Tilders; A M Van Dam
Journal:  Glia       Date:  2000-04       Impact factor: 7.452

5.  The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide.

Authors:  M Sato; M Kakubari; M Kawamura; J Sugimoto; K Matsumoto; T Ishii
Journal:  Biochem Pharmacol       Date:  2000-03-15       Impact factor: 5.858

6.  Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor.

Authors:  K Kosai; K Matsumoto; S Nagata; Y Tsujimoto; T Nakamura
Journal:  Biochem Biophys Res Commun       Date:  1998-03-27       Impact factor: 3.575

7.  Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia.

Authors:  Cristina P Marques; Shuxian Hu; Wen Sheng; Maxim C-J Cheeran; Diana Cox; James R Lokensgard
Journal:  Glia       Date:  2004-09       Impact factor: 7.452

8.  Adenoviral-mediated HGF expression inhibits germ cell apoptosis in rats with cryptorchidism.

Authors:  Kazumasa Goda; Masato Fujisawa; Toshiro Shirakawa; Masaki Dobashi; Goshi Shiota; Zhu Jun Zhang; Akinobu Gotoh; Sadao Kamidono
Journal:  J Gene Med       Date:  2004-08       Impact factor: 4.565

9.  Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.

Authors:  W M Mars; R Zarnegar; G K Michalopoulos
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

Review 10.  Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action.

Authors:  Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2004-07
View more
  3 in total

1.  Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model.

Authors:  Liang Sang; Xue-Mei Wang; Dong-Yang Xu; Li-Xuan Sang; Yang Han; Long-Yang Jiang
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

Review 2.  Therapeutic immunomodulation using a virus--the potential of inactivated orf virus.

Authors:  O Weber; A A Mercer; A Friebe; P Knolle; H-D Volk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-22       Impact factor: 5.103

3.  Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models.

Authors:  Daniela Paulsen; Andreas Urban; Andreas Knorr; Claudia Hirth-Dietrich; Angela Siegling; Hans-Dieter Volk; Andrew A Mercer; Andreas Limmer; Beatrix Schumak; Percy Knolle; Helga Ruebsamen-Schaeff; Olaf Weber
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.